-- Glaxo Tyverb, Roche Herceptin Rejected by U.K. Agency for Breast Cancer
-- B y   K r i s t e n   H a l l a m
-- 2010-12-15T00:01:00Z
-- http://www.bloomberg.com/news/2010-12-15/glaxo-tyverb-roche-herceptin-rejected-by-u-k-agency-for-breast-cancer.html
Using either GlaxoSmithKline Plc’s
Tyverb or Roche Holding AG’s Herceptin with another type of
breast cancer treatment didn’t offer enough value to patients to
justify the cost, the U.K. National Institute for Health and
Clinical Excellence said.  The agency, known as NICE, made the comments today in draft
guidance on the treatment of patients whose hard-to-treat breast
cancer has spread.  To contact the reporter on this story:
 Kristen Hallam  in London at 
 khallam@bloomberg.net   To contact the editor responsible for this story:
Phil Serafino at   pserafino@bloomberg.net  